If this also occurs in relation to second- and third-generation ALK–TKIs with activity against crizotinib-resistant ALK mutations, the EMT phenomenon could significantly compromise the possible use of next-generation ALK–TKIs as first-line treatment in ALK-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.